LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Ovid therapeutics Inc

Închisă

SectorSănătate

0.31 -3.12

Rezumat

Modificarea prețului

24h

Curent

Minim

0.3

Maxim

0.34

Indicatori cheie

By Trading Economics

Venit

-982K

-10M

Vânzări

54K

130K

EPS

-0.14

Marjă de profit

-7,873.077

Angajați

23

EBITDA

-1.8M

-12M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+732.35% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-4.3M

21M

Deschiderea anterioară

3.43

Închiderea anterioară

0.31

Sentimentul știrilor

By Acuity

50%

50%

162 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 iun. 2025, 20:51 UTC

Câștiguri

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 iun. 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 iun. 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 iun. 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 iun. 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 iun. 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 iun. 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 iun. 2025, 18:39 UTC

Market Talk
Câștiguri

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 iun. 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 iun. 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 iun. 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 iun. 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 iun. 2025, 17:08 UTC

Câștiguri

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 iun. 2025, 16:52 UTC

Achiziții, Fuziuni, Preluări

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 iun. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 iun. 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 iun. 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparație

Modificare preț

Ovid therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

732.35% sus

Prognoză pe 12 luni

Medie 2.83 USD  732.35%

Maxim 4 USD

Minim 1.5 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOvid therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

5

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.275 / 0.33Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

162 / 380 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.